Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

Hemstem

Financiado

Targeting leukaemia by modulating hematopoietic stem cell competitiveness

Human acute myeloid leukemia (AML) remains a devastating disease with less than 30% of patients surviving five years after diagnosis. Despite decades of research and detailed mo-lecular insights provided by mutational profiling, c... ver más

31/12/2025

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-02-25

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2019-COG: ERC Consolidator Grant

I+D

Cerrada hace 5 años

0% 100%

4 Participantes

1.74M€ | Lider

JAMON SALAMANCA, S.A.

290.63K€ | Participante

UNIVERSITAT BASEL

244.39K€ | Participante

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 70 meses Fecha Inicio: 2020-02-25
Fecha Fin: 2025-12-31

Líder del proyecto

EBERHARD KARLS UNIVERSITAET TUEBINGEN

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Human acute myeloid leukemia (AML) remains a devastating disease with less than 30% of patients surviving five years after diagnosis. Despite decades of research and detailed mo-lecular insights provided by mutational profiling, curative treatment still requires high-intensity chemotherapy and the crude approach of allogeneic stem cell transplantation – an effective, yet non-specific immunotherapy that is costly to the patient because of its severe side effects. One reason why the wealth of molecular and experimental knowledge has so far been unable to revolutionize treatments is the fact that AML is driven by small subpopulations of so-called leukemic stem cells (LSCs), which survive chemotherapy and immune surveillance. LSCs have growth advantages induced by oncogenic mutations, but are in many ways similar to healthy hematopoietic stem cells (HSCs). This similarity makes it difficult to target LSCs without simultaneously eradicating HSCs and healthy hematopoiesis derived from these cells. Like HSCs, LSCs home to protective bone marrow (BM) niches promoting stemness and therapy resistance and modify them to displace HSCs and promote their own expansion. This proposal explores strategies to target LSCs based on understanding these interactions. In Aim 1 we investigate how WNT signaling, an evolutionary conserved pathway governing stem cell self-renewal, regulates interactions between leukemic and healthy hematopoietic (stem) cells. In Aim 2, we propose to inhibit the in vivo expansion of LSCs by enhancing self-renewal and niche affinity in their natural competitors, the healthy stem cells with inborn BM homing ability. Aim 3 uses zebrafish to visualize LSC-HSC interactions and screens for molecules supporting healthy instead of (pre-) malignant hematopoiesis. Our studies will im-prove the knowledge on the complex interactions between LSCs and HSCs and provide a rationale for novel treatments that might lead to a paradigm-shift in the clinical management of AML.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores